Evidence map›Paper›PMID 34503166›Full record

ArticleCancers2021

The T/Tn-Specific

Mathias Simplicien, Annick Barre, Yamina Benkerrou, Els J M Van Damme, Pierre Rougé, Hervé Benoist

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Mathias SimplicienUMR 152 PharmaDev, Institut de Recherche et Développement, Faculté de Pharmacie, Université Paul, Sabatier, F-31062 Toulouse, France.ORCID 0000-0001-9303-5584
Annick BarreUMR 152 PharmaDev, Institut de Recherche et Développement, Faculté de Pharmacie, Université Paul, Sabatier, F-31062 Toulouse, France.ORCID 0000-0002-1360-8491
Yamina BenkerrouUMR 152 PharmaDev, Institut de Recherche et Développement, Faculté de Pharmacie, Université Paul, Sabatier, F-31062 Toulouse, France.
Els J M Van DammeDepartment of Biotechnology, Faculty of Bioscience Engineering, Ghent University, B-9000 Ghent, Belgium.ORCID 0000-0001-9848-766X
Pierre RougéUMR 152 PharmaDev, Institut de Recherche et Développement, Faculté de Pharmacie, Université Paul, Sabatier, F-31062 Toulouse, France.
Hervé BenoistUMR 152 PharmaDev, Institut de Recherche et Développement, Faculté de Pharmacie, Université Paul, Sabatier, F-31062 Toulouse, France.
Université Toulouse III - Paul Sabatier · FRGhent University · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Morniga G is a T/Tn-specific lectin, inducing cell death in Tn-positive leukemias but not in healthy lymphocytes.

Indexed as

biomedical applicationscancer cell deathHelix pomatia agglutininlectinsleukemiaMorniga GT lymphomatruncated O-glycansT/Tn antigens

Identifiers

PMID34503166
PMCPMC8431231
OpenAlexW3196912364

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.